Gapping down
In reaction to earnings/guidance:
- HWM -5.9%, GPN -5.1%, XPO -1.9%, MESO -1.4%, SAIA -1.1%
Other news:
- YMAB -45.9% (announces outcome of FDA Advisory Committee meeting on omburtamab)
- TIL -37.3% (announces voluntary pause of enrollment in ongoing clinical trials related to manufacturing)
- TSP -16.5% (lets go of CEO; initiates new CEO search)
- NUVL -3.6% (commenced an underwritten public offering of $200.0 mln of its shares of Class A common stock)
- MRNS -3.6% (announces revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5 million upfront)
- FOLD -3.3% (FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease)
- ASH -3% (FDA Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient in the review cycle of the FDA Novel Excipient Review Pilot Program)
- HLX -2% (files mixed securities shelf offering)
- ARGO -1.5% (Highlights Successful Transformation into a Focused, Pure-Play U.S. Specialty Insurer; Reiterates Commitment to Evaluating Alternatives to Maximize Shareholder Value)
- UTHR -1.3% (reports top line data from the EXPEDITE study of Remodulin induction prior to Orenitram therapy)
- META -0.8% (cautious Barron's article)
Analyst comments:
- AMD -1.3% (downgraded to Market Perform from Outperform at Northland Capital)
- ABB -1% (downgraded to Buy from Conviction Buy at Goldman)